Ceribell, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ

24 Feb 2026

CBLL

10-K: CeriBell Reports Strong Revenue Growth, Expands AI-Powered EEG Platform

CeriBell, Inc. announced a 36% revenue increase to $89.1 million in 2025, driven by expanded adoption of its AI-powered Ceribell System and new FDA clearances for delirium and pediatric/neonatal seizure monitoring, despite continued net losses.

NASDAQ

25 Feb 2025

CBLL

Ceribell, INC

10-K: CeriBell Reports Strong 2024 Revenue Growth, Focuses on Expanding Market Reach

CeriBell's 10-K filing reveals a 45% revenue increase in 2024, driven by wider adoption of its Ceribell System for neurological condition diagnosis.